Condition (MeSH)
Osteomalacia
ClinicalTrials.gov lists 34 trials for Osteomalacia or a narrower condition beneath it. Alexion Pharmaceuticals, Inc. has the most among industry and government lead sponsors, with 13.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
34 of the 34 trials are tagged with Osteomalacia itself; the rest are tagged with a narrower condition beneath it.
When did Osteomalacia trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2019 | 2 |
| 2017 | 1 |
| 2015 | 1 |
| 2014 | 4 |
| 2013 | 1 |
| 2012 | 3 |
| 2011 | 1 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 34 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Osteomalacia trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 3 |
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 2 |
| Not applicable | 2 |
| Observational | 15 |
| Expanded access | 1 |
How many Osteomalacia trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 25 |
| Approved for marketing | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Osteomalacia trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 13 |
| National Institute of Dental and Craniofacial Research (NIDCR) | 4 |
| Kyowa Kirin Co., Ltd. | 2 |
| Bagcilar Training and Research Hospital | 1 |
| Kyowa Kirin Korea Co., Ltd. | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Osteomalacia? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Asfotase Alfa | 10 |
| Burosumab | 3 |
| Calcium/Vitamin D | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 25 OH vitamin D | 1 |
| FGF23-related hypophosphataemic rickets and osteomalacia | 1 |
| 68Ga-DOTATATE PET/CT | 1 |
| Osteomalacia | 1 |
| Retrospective Case Only | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Osteomalacia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Craniosynostosis | 20 | 3 |
| Pneumonia | 13 | 3 |
| Convulsion | 7 | 3 |
| Pyrexia | 6 | 1 |
| Intracranial pressure increased | 5 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Osteomalacia? (50)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. | Endocrine reviews | 2018 | Yes |
| Tumour-induced osteomalacia. | Nature reviews. Disease primers | 2017 | Yes |
| Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. | Human molecular genetics | 2014 | Yes |
| Ovarian cancer-related hypophosphatemic osteomalacia--a case report. | The Journal of clinical endocrinology and metabolism | 2014 | Yes |
| Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | 2013 | Yes |
Showing 5 of 50 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.